Observational studyBMC nephrology2026
Clearance of small and middle molecules during continuous renal replacement therapy with the OMNI
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost continuous renal replacement therapy (CRRT) filter sets are designed for a maximum runtime of 72 h according to the manufacturer. A new filter set (OMNIset Pro® version 3.10) with an approved maximum runtime of 96 h has been proposed but has never been formally tested in critically ill patients.
methodsWe conducted a single-center prospective observational study to compare the performance of the new dialyzer with the previous generation and to assess the feasibility and efficacy of extending therapy up to 96 h in circuits that remains patent. Between January 2022 and February 2023 (period 2), we used the new OMNIset Pro® (version 3.10) in all patients admitted to our unit who required CRRT with the OMNI® (B Braun). Circuits lasting less than 24 h were excluded. We measured urea, creatinine, β2-microglobulin (ß2MG), and albumin levels in both plasma and effluent at 12, 24, 48, 72 and 96 h after circuit initiation. We computed effluent serum ratios (ESR) and clearances normalized to body mass for these molecules and compared results to similar measurements performed in patients admitted between September and December 2020 (period 1) who received CRRT using the old OMNIset Pro® (version 3.0). Comparisons were performed using mixed-models statistical analyses.
resultsWe included 42 circuits in 17 patients during period 1 and 50 circuits in 23 patients during period 2. Median lifespan was similar in both periods (57 h (IQR: 42–68) for period 1 and 50 h (IQR: 37–83) for period 2, p = 0.77). In period 2, 12 (24%) filters remained patent up to the 96 h limit. Median ESR for urea, creatinine and albumin were similar between the two periods. The ESR for creatinine presented a slight decrease over time of similar magnitude in both periods. The ESR for ß2MG remained stable for 96 h but was significantly lower in period 2 compared to period 1. New dialyzer enabled fluid removal and allowed rapid and sustained normalization of serum potassium and sodium levels, as well as metabolic acidosis.
conclusionsAmong circuits running ≥ 24 h, the new filter set showed similar solute clearance performance to the previous generation. In circuits that remained patent, sustained clearance was observed up to 96 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.